NCT05347498

A Trial of HR091506 Tablets in Treatment of Primary Gout With Hyperuricemia in Adults

Study on Efficacy and Safety of HR091506 Tablets in Treatment of Primary Gout With Hyperuricemia in Adults

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The study is being conducted to evaluate the efficacy and safety of HR091506 tablets for treatment of primary gout with hyperuricemia in adults, and to compare the results with febuxostat tablets in the same doses.

Conditions

• Primary Gout With Hyperuricemia in Adults

Interventions

Type	Name	Description
DRUG	HR091506 tablets + placebo of febuxostat tablets	HR091506 tablets 40mg qd + placebo of febuxostat tablets 40mg qd in Week 1 and 2, HR091506 tablets 80mg qd + placebo of febuxostat tablets 80mg qd in Week 3 and 4
DRUG	febuxostat tablets + placebo of HR091506 tablets	febuxostat tablets 40mg qd + placebo of HR091506 tablets 40mg qd in Week 1 and 2, febuxostat tablets 80mg qd + placebo of HR091506 tablets 80mg qd in Week 3 and 4

Timeline

• Start date: 2022-04-30
• Primary completion: 2022-07-31
• Completion: 2022-07-31
• First posted: 2022-04-26
• Last updated: 2022-04-26